{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T09:01:49Z","timestamp":1770714109965,"version":"3.49.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Data on direct oral anticoagulants (DOACs) in venous thrombotic antiphospholipid antibody syndrome (APS) are controversial. This pilot study aimed to assess the safety and efficacy of DOACs in APS patients requiring oral anticoagulation for venous thromboembolism (VTE) but unsuitable for treatment with vitamin K antagonists (VKAs). We performed a prospective multi-centre case-series including APS patients with previous VTE who were receiving treatment with DOACs due to ineligibility for VKAs. Main outcomes were bleeding, arterial and recurrent venous thrombotic events and all-cause death. We included 18 patients (median age 59.6 years, 66.7% women). The antiphospholipid antibody pattern was single positivity for 33.3% patients, double positivity for 33.3%, and triple positivity for 27.8%. Only one patient had seronegative APS. Apixaban, dabigatran, rivaroxaban and edoxaban were prescribed in 44.4%, 27.8%, 16.7% and 11.1% of patients, respectively. The mean follow-up was 50.1\u2009\u00b1\u200924.1 months. During the observation period, no recurrent VTE episodes or arterial thrombotic events were recorded. Four bleedings, of which 2 major, were reported. The incidence rate of bleeding was 5.3 per 100 patient-years (95% confidence interval [95%CI] 1.4\u201313.6). No intracranial bleedings were recorded.<\/jats:p>\n                  <jats:p>In conclusion, our preliminary findings may suggest DOAC as possible option for patients with venous thrombotic APS unsuitable to VKAs. Although these findings are promising, larger cohort studies are needed to confirm this finding.<\/jats:p>","DOI":"10.1007\/s11239-025-03158-3","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T09:23:39Z","timestamp":1756459419000},"page":"220-227","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term efficacy and safety of direct oral anticoagulants in venous thrombotic antiphospholipid syndrome patients not candidate to warfarin: A pilot prospective case series study"],"prefix":"10.1007","volume":"59","author":[{"given":"Daniele","family":"Pastori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danilo","family":"Menichelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gian Marco","family":"Podda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bianca","family":"Clerici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Birocchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tommaso","family":"Bucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul RJ","family":"Ames","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pasquale","family":"Pignatelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"issue":"9","key":"3158_CR1","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1001\/jama.295.9.1050","volume":"295","author":"W Lim","year":"2006","unstructured":"Lim W, Crowther MA, Eikelboom JW (2006) Management of antiphospholipid antibody syndrome: a systematic review. JAMA: J Am Med Association 295(9):1050\u20131057. https:\/\/doi.org\/10.1001\/jama.295.9.1050","journal-title":"JAMA: J Am Med Association"},{"issue":"10","key":"3158_CR2","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1016\/j.jtha.2023.06.020","volume":"21","author":"H Cohen","year":"2023","unstructured":"Cohen H, Werring DJ, Chandratheva A, Mittal P, Devreese KMJ, Isenberg DA et al (2023) Survey on antiphospholipid syndrome diagnosis and antithrombotic treatment in patients with ischemic stroke, other brain ischemic injury, or arterial thromboembolism in other sites: communication from ISTH SSC subcommittee on lupus anticoagulant\/antiphospholipid antibodies. J Thromb Haemost 21(10):2963\u20132976. https:\/\/doi.org\/10.1016\/j.jtha.2023.06.020","journal-title":"J Thromb Haemost"},{"issue":"2","key":"3158_CR3","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/ene.13499","volume":"25","author":"M Radin","year":"2018","unstructured":"Radin M, Schreiber K, Cecchi I, Roccatello D, Cuadrado MJ, Sciascia S (2018) The risk of ischaemic stroke in primary antiphospholipid syndrome patients: a prospective study. Eur J Neurol 25(2):320\u2013325. https:\/\/doi.org\/10.1111\/ene.13499","journal-title":"Eur J Neurol"},{"issue":"5","key":"3158_CR4","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1111\/j.1538-7836.2005.01340.x","volume":"3","author":"G Finazzi","year":"2005","unstructured":"Finazzi G, Marchioli R, Brancaccio V, Schinco P, Wisloff F, Musial J et al (2005) A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemostasis: JTH 3(5):848\u2013853. https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01340.x","journal-title":"J Thromb Haemostasis: JTH"},{"key":"3158_CR5","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.atherosclerosis.2015.10.105","volume":"244","author":"D Pastori","year":"2016","unstructured":"Pastori D, Parrotto S, Vicario T, Saliola M, Mezzaroma I, Violi F et al (2016) Antiphospholipid syndrome and anticoagulation quality: a clinical challenge. Atherosclerosis 244:48\u201350. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2015.10.105","journal-title":"Atherosclerosis"},{"issue":"3","key":"3158_CR6","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.autrev.2013.10.014","volume":"13","author":"L Arnaud","year":"2014","unstructured":"Arnaud L, Mathian A, Ruffatti A, Erkan D, Tektonidou M, Cervera R et al (2014) Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis. Autoimmun Rev 13(3):281\u2013291. https:\/\/doi.org\/10.1016\/j.autrev.2013.10.014","journal-title":"Autoimmun Rev"},{"issue":"FI1","key":"3158_CR7","doi-asserted-by":"publisher","first-page":"f11","DOI":"10.1093\/ehjcvp\/pvab002","volume":"7","author":"D Menichelli","year":"2021","unstructured":"Menichelli D, Del Sole F, Di Rocco A, Farcomeni A, Vestri A, Violi F et al (2021) Real-world safety and efficacy of direct oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of 605 771 patients. Eur Heart J Cardiovasc Pharmacother 7(FI1):f11\u2013f9. https:\/\/doi.org\/10.1093\/ehjcvp\/pvab002","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"13","key":"3158_CR8","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","volume":"132","author":"V Pengo","year":"2018","unstructured":"Pengo V, Denas G, Zoppellaro G, Jose SP, Hoxha A, Ruffatti A et al (2018) Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 132(13):1365\u20131371. https:\/\/doi.org\/10.1182\/blood-2018-04-848333","journal-title":"Blood"},{"key":"3158_CR9","doi-asserted-by":"publisher","first-page":"715878","DOI":"10.3389\/fcvm.2021.715878","volume":"8","author":"D Pastori","year":"2021","unstructured":"Pastori D, Menichelli D, Cammisotto V, Pignatelli P (2021) Use of direct oral anticoagulants in patients with antiphospholipid syndrome: A systematic review and comparison of the international guidelines. Front Cardiovasc Med 8:715878. https:\/\/doi.org\/10.3389\/fcvm.2021.715878","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"3158_CR10","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","volume":"4","author":"S Miyakis","year":"2006","unstructured":"Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4(2):295\u2013306. https:\/\/doi.org\/10.1111\/j.1538-7836.2006.01753.x","journal-title":"J Thromb Haemost"},{"issue":"3","key":"3158_CR11","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1055\/s-0038-1651587","volume":"69","author":"FR Rosendaal","year":"1993","unstructured":"Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E (1993) A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 69(3):236\u2013239","journal-title":"Thromb Haemost"},{"key":"3158_CR12","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.dib.2018.01.109","volume":"17","author":"D Pastori","year":"2018","unstructured":"Pastori D, Lip GYH, Farcomeni A, Del Sole F, Sciacqua A, Perticone F et al (2018) Data on incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants. Data Brief 17:830\u2013836. https:\/\/doi.org\/10.1016\/j.dib.2018.01.109","journal-title":"Data Brief"},{"issue":"11","key":"3158_CR13","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1177\/09612033221118463","volume":"31","author":"YH Lee","year":"2022","unstructured":"Lee YH, Song GG (2022) Direct oral anticoagulants versus warfarin in patients with antiphospholipid syndrome: A meta-analysis of randomized controlled trials. Lupus 31(11):1335\u20131343. https:\/\/doi.org\/10.1177\/09612033221118463","journal-title":"Lupus"},{"issue":"1","key":"3158_CR14","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jacc.2022.10.008","volume":"81","author":"CD Khairani","year":"2023","unstructured":"Khairani CD, Bejjani A, Piazza G, Jimenez D, Monreal M, Chatterjee S et al (2023) Direct oral anticoagulants vs vitamin K antagonists in patients with antiphospholipid syndromes: Meta-Analysis of randomized trials. J Am Coll Cardiol 81(1):16\u201330. https:\/\/doi.org\/10.1016\/j.jacc.2022.10.008","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"3158_CR15","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/FJC.0000000000001578","volume":"84","author":"M Sikorska","year":"2024","unstructured":"Sikorska M, Chmiel J, Papuga-Szela E, Broniatowska E, Undas A (2024) Apixaban versus vitamin K antagonists in patients with antiphospholipid syndrome: A cohort study. J Cardiovasc Pharmacol 84(1):36\u201344. https:\/\/doi.org\/10.1097\/FJC.0000000000001578","journal-title":"J Cardiovasc Pharmacol"},{"issue":"4","key":"3158_CR16","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","volume":"41","author":"SV Konstantinides","year":"2020","unstructured":"Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP et al (2020) 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European respiratory society (ERS). Eur Heart J 41(4):543\u2013603. https:\/\/doi.org\/10.1093\/eurheartj\/ehz405","journal-title":"Eur Heart J"},{"issue":"19","key":"3158_CR17","doi-asserted-by":"publisher","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","volume":"4","author":"TL Ortel","year":"2020","unstructured":"Ortel TL, Neumann I, Ageno W, Beyth R, Clark NP, Cuker A et al (2020) American society of hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv 4(19):4693\u20134738. https:\/\/doi.org\/10.1182\/bloodadvances.2020001830","journal-title":"Blood Adv"},{"issue":"8","key":"3158_CR18","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1207541","volume":"368","author":"G Agnelli","year":"2013","unstructured":"Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M et al (2013) Apixaban for extended treatment of venous thromboembolism. N Engl J Med 368(8):699\u2013708. https:\/\/doi.org\/10.1056\/NEJMoa1207541","journal-title":"N Engl J Med"},{"issue":"13","key":"3158_CR19","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1056\/NEJMoa1700518","volume":"376","author":"JI Weitz","year":"2017","unstructured":"Weitz JI, Lensing AWA, Prins MH, Bauersachs R, Beyer-Westendorf J, Bounameaux H et al (2017) Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med 376(13):1211\u20131222. https:\/\/doi.org\/10.1056\/NEJMoa1700518","journal-title":"N Engl J Med"},{"issue":"6","key":"3158_CR20","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1182\/bloodadvances.2021005808","volume":"6","author":"SC Woller","year":"2022","unstructured":"Woller SC, Stevens SM, Kaplan D, Wang TF, Branch DW, Groat D et al (2022) Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial. Blood Adv 6(6):1661\u20131670. https:\/\/doi.org\/10.1182\/bloodadvances.2021005808","journal-title":"Blood Adv"},{"issue":"2","key":"3158_CR21","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1182\/blood-2014-01-548065","volume":"124","author":"G Palareti","year":"2014","unstructured":"Palareti G, Cosmi B, Legnani C, Antonucci E, De Micheli V, Ghirarduzzi A et al (2014) D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study. Blood 124(2):196\u2013203. https:\/\/doi.org\/10.1182\/blood-2014-01-548065","journal-title":"Blood"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-025-03158-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-025-03158-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-025-03158-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T13:41:47Z","timestamp":1770644507000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-025-03158-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["3158"],"URL":"https:\/\/doi.org\/10.1007\/s11239-025-03158-3","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]},"assertion":[{"value":"18 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}